Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV. A cross-sectional population-based study.
de Lazzari E, Nomah DK, Blanco JL, Rico N, Filella X, Egri N, Ruiz R, Marcos MA, Mosquera MDM, Alcamí J, Sánchez-Palomino S, Bruguera A, Hurtado C, Rovira C, Ambrosioni J, Chivite I, González-Cordón A, Inciarte A, Laguno M, Martínez-Rebollar M, Mora L, Torres B, Díaz Y, Martínez E, Mallolas J, Miro JM; Hospital Clinic HIV investigators.
de Lazzari E, et al. Among authors: blanco jl.
Int J Infect Dis. 2024 Oct 16:107266. doi: 10.1016/j.ijid.2024.107266. Online ahead of print.
Int J Infect Dis. 2024.
PMID: 39423949
Free article.